NEW YORK, May 08, 2023 (GLOBE NEWSWIRE) — Attorney Advertising – Bronstein, Gewirtz & Grossman, LLC is notifying investors that a class action lawsuit has been filed against Fulcrum Therapeutics, Inc. (“Fulcrum” or the “Company”) FULC and certain of its officers on behalf of all persons and entities that purchased or otherwise acquired Fulcrum securities between March 3, 2022 and March 8, 2023, both dates inclusive (the “Collection Period”). Such investors are encouraged to join this case by visiting the company’s website: www.bgandg.com/fulc.

This class action seeks damages against the defendants for alleged violations of federal securities laws.

The lawsuit alleges that the defendants made materially false and misleading statements regarding the company’s FDA operational and compliance policies during the class-action period. In particular, the defendants made false and/or misleading statements and/or failed to disclose that: (1) the preclinical data presented in support of FTX-6058 revealed safety concerns related to possible hematological malignancies; (2) the foregoing safety concerns increased the likelihood that the FDA would suspend clinical trials of FTX-6058; (3) accordingly, the company had overstated the clinical and/or commercial prospects of FTX-6058; and (4) as a result, the Company’s public statements were, at all relevant times, materially false and misleading.

A class action lawsuit has already been filed. If you would like to see a copy of the complaint, you can visit the firm’s website: www.bgandg.com/fulc or you can contact Peretz Bronstein, Esq. or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Fulcrum, you have until June 27, 2023 to apply for the court to appoint you lead plaintiff. Your ability to participate in a recovery does not require you to serve as lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC represents…